CLASS II Drug recall · Reported 21 Jul 2021 · FDA Enforcement Report

Solifenacin Succinate Tablets, 10 mg recalled by CIPLA

CIPLA is recalling Solifenacin Succinate Tablets, 10 mg, distributed nationwide in the US. The recall was initiated on 10 Jun 2021 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: GG90819, Exp. Date 06/2021
Quantity recalled7228 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0660-2021
FDA event ID
88090
Recalling firm
CIPLA, Warren, NJ
Classification
Class II
Status
Terminated
Recall initiated
10 Jun 2021
FDA classified
15 Jul 2021
Reported
21 Jul 2021
Type
Voluntary: Firm initiated
Customers notified by
Letter

Timeline

10 Jun 2021Recall initiated by company
15 Jul 2021Classified by FDA+35 days
21 Jul 2021Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations

Product as listed by the FDA

Solifenacin Succinate Tablets, 10 mg, 30-count bottles, Rx Only, Manufactured by: Cipla Ltd., Verna, Goa, India Manufactured for Cipla USA, Inc. 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL, 33323, NDC 69097-261-02.

Where it was distributed

Nationwide within the United States

Nationwide

Questions about this recall

Is Solifenacin Succinate Tablets, 10 mg recalled?

Yes. CIPLA recalled Solifenacin Succinate Tablets, 10 mg on 10 Jun 2021. The recall is Class II and its status is Terminated. Recall number D-0660-2021.

Why was it recalled?

CGMP Deviations

Which lots are affected?

Lot #: GG90819, Exp. Date 06/2021

Where was it sold?

Nationwide within the United States

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from CIPLA

All 14
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIPhytonadione Injectable Emulsion, USP 10mg/mL recalled by CiplaPhytonadioneCiplaPotency & AssayNationwide
DrugCLASS IIArformoterol Tartrate Inhalation Solution recalled by CIPLAArformoterol TartrateCIPLASterilityNationwide
DrugCLASS IIBudesonide Inhalation Suspension 25mg/, For Inhalation Only recalledBudesonideCIPLASterilityNationwide
DrugCLASS IIDifluprednate Ophthalmic Emulsion recalled by CIPLADifluprednateCIPLASterilityNationwide
DrugCLASS IIDifluprednate Ophthalmic Emulsion recalled by CIPLACIPLASterilityNationwide

Other Solifenacin recalls

All 6